ERBB2 and neoplasm: However, HER2-DC1 s.c. combined with anti-HER2 antibodies treatment failed to induce enhanced anti-HER2 Th1 immune response in the tumor draining lymph node and peripheral blood, which further supports the inability of generating strong and sustained antitumor immunity for this combination treatment approach in a HER2pos BC model.